Market Overview

Repligen To Report Third Quarter of 2012 Financial Results

Share:
WALTHAM, Mass.--(BUSINESS WIRE)--

Repligen Corporation (NASDAQ: RGEN) today announced that it will report financial results for the third quarter of 2012 before the NASDAQ Global Market opens on Thursday, November 8. The earnings press release will be followed by a conference call and webcast at 9:00 a.m. EST. The event will be hosted by Walter C. Herlihy, Ph.D., President and CEO of Repligen, who will discuss financial results for the third quarter and year-to-date and provide a corporate update.

Repligen's third quarter conference call will be accessible by dialing (800) 260-8140 for domestic callers or (617) 614-3672 for international callers. Dial-in participants must provide the passcode 85324503. Alternatively, an audio webcast will be accessible via the Investors section of Repligen's website www.repligen.com. Both the conference call and webcast will be archived for a period of time following the live event. The replay dial-in numbers are (888) 286-8010 for domestic callers and (617) 801-6888 for international callers. Replay listeners must provide the passcode 97138968.

About Repligen Corporation

Repligen Corporation is a life sciences company focused on the development, production and commercialization of products used in the process of manufacturing biological drugs. Our bioprocessing products are sold to major life sciences and biopharmaceutical companies worldwide. We are a leading manufacturer of Protein A, a critical reagent used to manufacture monoclonal antibody-based therapeutics. We also supply several growth factor products used to increase cell culture productivity in biomanufacturing. In the burgeoning area of disposable biomanufacturing technologies, we have developed and market a series of OPUS® (Open Platform User Specified) single-use chromatography columns used in the biologics purification process. In addition to our core bioprocessing business, we have a portfolio of clinical-stage partnering assets, including two central nervous system orphan drug candidates and a pancreatic imaging agent in Phase 3 development. Repligen's corporate headquarters are located in Waltham, MA, USA, with an additional manufacturing facility in Lund, Sweden. For more information, please visit our website at www.repligen.com.

This press release may contain forward-looking statements within the meaning of the federal securities laws. Investors are cautioned that statements in this press release which are not strictly historical statements including, without limitation, statements identified by words like “believe,” “expect,” “may,” “will,” “should,” “seek,” or “could” and similar expressions, constitute forward-looking statements. Such forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated, including, risks discussed from time to time in our filings with the Securities and Exchange Commission. We expressly disclaim any responsibility to update forward-looking statements, except as required by law.

Repligen Corporation
Sondra Newman, 781-419-1881
Director Investor Relations
snewman@repligen.com

View Comments and Join the Discussion!